Top Bristol Healthtech Companies (11)
Don't see your company?
Create a company profile
We monitor eye health at home. We are developing the first digital bio markers of the eye, by tracking visual interactions with smart devices. Our vision is to predict eye and wellness disorders ahead of time.
eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, eXmoor has specialized in the CGT sector since 2007 helping organisations to understand, plan and implement the appropriate CMC strategy. eXmoor does this via its translational and capital consulting groups, process and analytical development labs and now GMP manufacturing capability. eXmoor has completed over 500 projects for 150 clients and is headquartered in Bristol, UK, with 70 current employees, growing to 200 by 2027.
TalkLife is an innovative peer support mental health platform that helps millions of people across the world navigate the ups and downs of life. We use the best elements of social networking mashed with peer-to-peer support and connect people around the globe within a safe and encouraging environment. Using our extensive experience in building incredible peer support communities, we've developed tailored platforms TalkCampus for the student population, and TalkLife Workplace to support employee mental health. Since joining the community: 86% of users find it easier to ask for help when they need it 82% of them feel more understood by others 79% feel more able to cope with life We work alongside the world's best machine learning & psychology minds from MIT, Harvard University and Microsoft Research through our Project Valinor - using machine learning to predict and launch digital interventions for those at risk. We maintain a high-performance culture marked by fearlessness and hyper-productivity. We’re after team players with natural product intuition who can work harder, faster, and smarter without sacrificing technical excellence. Our organisational challenges are unique, so you should be comfortable in uncharted territory and pumped to build systems that can support a growing number of users around the globe
Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent the previously existing bio-design limits of conventional peptide synthesis with one universal process.
Our vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats
Do the work of your life to help the lives of others. As a leading health technology company, it is our purpose to improve people’s health and well-being through meaningful innovation. Our goal is to improve 2.5 billion lives per year by 2030. We also strive to be the best place to work for people who share our passion, by promoting personal development, inclusion and diversity while acting responsibly towards our planet and society.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries. To learn more, visit www.iqvia.com.
We develop diagnostics that are fast, accurate and can be used at the point of care: ensuring the first prescription, is always the right prescription. Our technologies answer 2 vital questions to ensure effective and sustainable use of antibiotics: Does the patient have an infection treatable with antibiotics? NANOPLEX® is an advanced latex agglutination test that can be used to rapidly identify and quantify the cause of infection in 5 minutes. What will be the most effective antibiotic treatment? SCFI™ is a phenotypic, real-time and growth-free antibiotic susceptibility test that determines the most effective antibiotic in 30 minutes.
Micrima was founded in 2005 to develop and commercialise microwave radar breast imaging technology initially pioneered at the University of Bristol in the UK. The company's MARIA system is currently in clinical trials to collect valuable data for our machine learning algorithm's. The latest step in the journey to Breast Screening will be launched in 2022. This new system will provide density information and improved ergonomics for patient and operator. Contact us to arrange to see this system or to find out more
Ceryx Medical are an exciting new Medtech company developing a range of innovative bioelectronic devices. These devices use a unique chip technology which is able to mimic nerve centres within the body called central pattern generators. These CPGs help to control a range of autonomic or rhythmical processes such as peristalsis, heart rate and even walking. It is hoped that Ceryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury.
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, having many unique qualities compared to systemic administration of therapeutic protein, including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the tRBC, thereby shielding them from the immune system. Born out of more than a decade of research at the University of Bristol and its learnings from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells
Work Your Passion. Live Your Purpose.
